News
 and trophoblastweb.png)
Research on the human placenta as a target of SARS-CoV-2
New in vitro model: an alternative method to animal testing.
Which virus is behind the flu?
Why are we seeing recurring infections with avian influenza A viruses? How high is the zoonotic potential of animal influenza viruses?What research is the IVI doing on influenza viruses? Current interview with Dr Gert Zimmer, a virologist at the Institute of Virology and Immunology (IVI) and the University of Bern.
News from the IVI on cases in Switzerland
Releases
Java script is required to display press releases. If you are unable or unwilling to activate Java script you may use the link below to access the Federal Administration News Portal, where you can read the announcements.
In focus
SARS-CoV-2 : a nasal vaccine in the pipeline
With the support of the Swiss National Science Foundation, Volker Thiel, virologist, and his team at the Institute of Virology and Immunology IVI and at the University of Berne, are developing a live attenuated vaccine. In order to ensure the required clinical trials RocketVax AG has concluded a new partnership with a research consortium. Press release
Newcastle disease virus
The IVI is currently analysing further samples from a poultry farm in Jura for NDV virus genome and positive samples will subsequently be pathotyped.
Rabies
Rabies in Switzerland: a daily battle. If a case of rabies is suspected, prompt action is vital to protect potentially exposed humans against this deadly zoonosis.
.png)
Blog - Young researchers from the IVI
Thao Tran : "we only required the sequencing data from the virus-of-interest, and from this we could synthesise the building blocks to construct the synthetic virus using the yeast-based platform".
In cooperation with Vetsuisse Faculty
www.ivi.unibe.ch